Is Grail Stock a Bad-News Buy After Its Recent Pullback?
Key takeaways
- ILMN NVDA INTC Grail s (NASDAQ: GRAL) stock closed at a record high of $116.06 in January.
- High expectations for Grail s Galleri blood test, which aims to detect signals from dozens of cancers before any symptoms appear, initially drove its stock higher.
- Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need.
ILMN NVDA INTC Grail s (NASDAQ: GRAL) stock closed at a record high of $116.06 in January. That marked a 732% gain from its $13.95 opening price following its spin-off from Illumina (NASDAQ: ILMN) in June 2024. But as of this writing, it trades at about $68.
High expectations for Grail s Galleri blood test, which aims to detect signals from dozens of cancers before any symptoms appear, initially drove its stock higher. But its stock plummeted in February after its largest NHS England trial for Galleri failed to meet its primary endpoint. Does that pullback represent a buying opportunity for investors who can tune out the near-term noise?
Will AI create the world s first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »